Travel considerations specified for 177Lu-DOTATATE radiation therapy patients

(Society of Nuclear Medicine and Molecular Imaging) Researchers and patient advocates have addressed the challenges related to traveling after receiving 177Lu-DOTATATE radiation therapy in a study published in the April issue of The Journal of Nuclear Medicine. Due to the residual radiation activity of 177Lu-DOTATATE, neuroendocrine tumor patients have experienced travel delays at U.S. ports of entry. Researchers recommend that patients carry a travel card containing treatment information after each therapy cycle and for an additional three months after therapy has concluded.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news